Patents Examined by Khaleda B Hasan
-
Patent number: 11685942Abstract: A method of making a polypeptide including one or more D-amino acids is provided. The method includes combining a ribosome with protein translation factors including (1) a template encoding the polypeptide, wherein the template encoding the polypeptide includes one or more codons which have been recoded to accept a tRNA attached to a D-amino acid, (2) a plurality of L-amino acids and a plurality of corresponding tRNAs, (3) a plurality of D-amino acids and their corresponding aminoacyl tRNA synthetase or a plurality of tRNAs ligated with a D-amino acid, and (4) elongation factor P in a concentration of 2 to 20 micromolar, wherein translation of the template encoding the polypeptide occurs to produce the polypeptide including one or more D-amino acids.Type: GrantFiled: March 3, 2017Date of Patent: June 27, 2023Assignee: President and Fellows of Harvard CollegeInventors: George M. Church, Po-Yi Huang
-
Patent number: 11667932Abstract: The present disclosure provides a sphere-packing lattice electroporation device configured for use as a stand-alone unit or in an automated multi-module cell processing environment and configured to decrease cell processing time and cell survival. The sphere-packing lattice utilizes lattice-forming beads that are uniform in size and that self-assemble into a crystalline-like lattice.Type: GrantFiled: November 10, 2021Date of Patent: June 6, 2023Assignee: Inscripta, Inc.Inventors: Christian Siltanen, Megan Basila
-
Patent number: 11613757Abstract: The present invention discloses a process for the secretion of brazzein in improved yield.Type: GrantFiled: January 27, 2017Date of Patent: March 28, 2023Assignee: MAGELLAN LIFE SCIENCES LTD.Inventors: Abhiram Dukkipati, Aakruthi Vasihnavi Balagangadhar
-
Patent number: 11597924Abstract: The application provides improved methods of genome editing. The genome editing systems described herein comprise a RNA-guided nuclease molecule and a Repair-Modulating Enzyme Molecule (RMEM).Type: GrantFiled: March 24, 2017Date of Patent: March 7, 2023Assignee: Editas Medicine, Inc.Inventors: Cecilia Cotta-Ramusino, Anne Helen Bothmer
-
Patent number: 11591592Abstract: This invention relates to compositions of matter, methods, modules and automated, end-to-end closed instruments for automated mammalian cell growth, reagent bundle creation and mammalian cell transfection followed by nucleic acid-guided nuclease editing in live mammalian cells. The disclosed compositions and method entail making “reagent bundles” comprising many (hundreds of thousands to millions) clonal copies of an editing cassette and delivering or co-localizing the reagent bundles with live mammalian cells such that the editing cassettes edit the cells and the edited cells continue to grow.Type: GrantFiled: April 23, 2021Date of Patent: February 28, 2023Assignee: Inscripta, Inc.Inventors: Phillip Belgrader, Nathan Bade, Christian Siltanen, Aamir Mir, Xi-Jun Chen, Janine Mok, Burak Dura, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
-
Patent number: 11578340Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: GrantFiled: October 13, 2017Date of Patent: February 14, 2023Assignees: University of Massachusetts, Sichuan UniversityInventors: Guangping Gao, Guangchao Xu, Phillip Tai, Yuquan Wei, Li Luo
-
Patent number: 11578312Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems. In particular the present invention comprehends engineered new guide architectures and enzymes to be used in optimized Staphylococcus aureus CRISPR-Cas enzyme systems.Type: GrantFiled: December 12, 2017Date of Patent: February 14, 2023Assignees: THE BROAD INSTITUTE INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, UNIVERSITY OF TOKYOInventors: Feng Zhang, Winston Yan, Osamu Nureki, Kaijie Zheng, Le Cong, Hiroshi Nishimasu, Fei Ran, Yinqing Li
-
Patent number: 11459559Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.Type: GrantFiled: October 21, 2016Date of Patent: October 4, 2022Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
-
Patent number: 11358993Abstract: Described herein are recombinant AAV vectors comprising a polynucleotide sequence comprising ?-sarcoglycan and methods of using the recombinant vectors to reduce or prevent fibrosis in a mammalian subject suffering from a muscular dystrophy. Also described herein are combination therapies comprising administering AAV vector(s) expressing ?-sarcoglycan and miR-29c to a mammalian subject suffering from a muscular dystrophy.Type: GrantFiled: April 14, 2017Date of Patent: June 14, 2022Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITALInventors: Louise Rodino-Klapac, Jerry R. Mendell
-
Patent number: 11345930Abstract: The present disclosure provides codon optimized RPGRorf15 sequences, vectors, and host cells comprising codon optimized RPGRorf15 sequences, and methods of treating retinal disorders such as XLRP comprising administering to the subject a codon optimized RPGRorf15 sequence.Type: GrantFiled: August 30, 2021Date of Patent: May 31, 2022Assignee: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa A. Kotterman, David Schaffer, Peter Francis
-
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
Patent number: 11338045Abstract: The invention provides gene therapy vectors, such as adeno-associated vims (AAV) vectors, expressing a functional fragment of the miniaturized human micro-dystrophin gene and method of using these vectors to express the fragment of micro-dystrophin in skeletal muscles including diaphragm and cardiac muscle and to protect muscle fibers from injury, increase muscle strength and reduce and/or prevent fibrosis in subjects suffering from muscular dystrophy.Type: GrantFiled: March 16, 2018Date of Patent: May 24, 2022Assignees: NEWCASTLE UNIVERSITY, University of HeidelbergInventors: Hanns Lochmuller, Oliver Muller -
Patent number: 11337997Abstract: It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.Type: GrantFiled: March 15, 2017Date of Patent: May 24, 2022Assignee: Yamaguchi UniversityInventors: Koji Tamada, Yukimi Sakoda, Keishi Adachi
-
Patent number: 11339436Abstract: The present invention relates to the discovery that the expression levels of some RNA molecules, comprising messenger RNA (mRNA), non-coding RNA (ncRNA) and/or microRNA (miRNA), and protein can be used as a diagnostic signature to predict or monitor the bone healing ability in an acutely injured subject or in a chronic nonunion subject. In certain embodiments, the invention relates to methods and compositions useful for differentiating between a nonunion, slow healing, and/or normal healing of a fractured bone and treatment recommendations. The invention further includes a kit comprising biomarker probes for assessing the bone healing ability in an acutely injured subject or in a nonunion subject after receiving therapeutic treatment.Type: GrantFiled: February 3, 2016Date of Patent: May 24, 2022Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Annamarie D. Horan, Samir Mehta, Donald A. Baldwin
-
Patent number: 11332760Abstract: The present disclosure provides donor polynucleotides, genome editing systems, methods, pharmaceutical compositions, and kits which correct or induce a mutation that causes Glycogen Storage Disease 1a in a genomic DNA (gDNA) molecule in a cell. In some embodiments the present disclosure provides donor polynucleotides comprising two strands capable of correcting a mutation that causes Glycogen Storage Disease 1a.Type: GrantFiled: February 18, 2021Date of Patent: May 17, 2022Assignee: CRISPR THERAPEUTICS AGInventors: Troy Dean Carlo, Roman Lvovitch Bogorad
-
Patent number: 11306329Abstract: Provided herein are adeno-associated virus (AAV) compositions that can restore F8 gene function in a cell without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease. Also provided are methods of using the AAV compositions to correct an F8 gene mutation and/or treat a disease or disorder associated with an F8 gene mutation. Packaging systems for making the adeno-associated virus compositions are also provided.Type: GrantFiled: February 19, 2019Date of Patent: April 19, 2022Assignees: CITY OF HOPE, HOMOLOGY MEDICINES, INC.Inventors: Saswati Chatterjee, Laura Jane Smith, Jeff Lynn Ellsworth, Hillard Rubin, Jason Boke Wright, James Anthony McSwiggen
-
Patent number: 11286505Abstract: A method to produce protein in Aspergillus niger's sleeping spores using single-stranded RNA is provided. The method includes three steps: culture of Aspergillus niger and collection of spores, pretreatment of Aspergillus niger spores, and electroporation of Aspergillus niger spores using HDEN method. Non-germinated spores are used as a starting material for introduction of exogenous molecules. The exogenous protein coding single-stranded RNA is introduced into the resting spores of Aspergillus niger by employing the HDEN electrotransformation technique to express protein. This method is simple and fast, the effect is excellent, and the transformation rate reaches more than 90%.Type: GrantFiled: March 8, 2019Date of Patent: March 29, 2022Inventor: Jun Lin
-
Patent number: 11225674Abstract: The present disclosure provides a sphere-packing lattice electroporation device configured for use as a stand-alone unit or in an automated multi-module cell processing environment and configured to decrease cell processing time and increase cell survival. The sphere-packing lattice utilizes lattice-forming beads that are uniform in size and that self-assemble into a crystalline-like lattice.Type: GrantFiled: January 26, 2021Date of Patent: January 18, 2022Assignee: Inscripta, Inc.Inventors: Christian Siltanen, Megan Basila
-
Patent number: 11193124Abstract: A method of preparing a library of small interfering RNA (siRNA) expression systems for producing siRNA for silencing of target genes by inducing degradation of target gene RNA expression products includes: (i) isolating RNA of one or more target genes from a cell population; (ii) generating RNA fragments from the isolated RNA; (iii) converting the RNA fragments into dsDNA fragments; and (iv) cloning the dsDNA fragments into vectors for forming cloned vectors, each vector including one or more promoters and at least one restriction enzyme site capable of accepting the insertion of at least one dsDNA fragment such that siRNA can be produced. Methods for producing siRNA from the siRNA expression system and methods of identifying a functional target gene for treatment by using the siRNA produced from the siRNA expression system and for identifying RNAi therapeutics are also provided.Type: GrantFiled: November 15, 2016Date of Patent: December 7, 2021Assignee: City University of Hong KongInventors: Linfeng Huang, Yutian Ren, Hung-chi Cheung, Guneet Kaur
-
Patent number: 11193123Abstract: Provided herein are compositions and methods for increasing editing efficiency of a target nucleic acid. A composition may comprise a guide nucleic acid, a Cas9 nickase, or a reverse transcriptase. The reverse transcriptase may be fused to the Cas9 nickase. The reverse transcriptase may heterodimerize with the Cas9 nickase. The reverse transcriptase may bind to a guide nucleic acid. The reverse transcriptase may be engineered to increase processivity. The guide nucleic acid may be engineered to facilitate synthesis or editing of a sequence. The guide nucleic acid, Cas9 nickase, and reverse transcriptase may be engineered to fit within AAV vectors. The guide nucleic acid may comprise a region that binds to another region on the guide nucleic acid to improve gene editing.Type: GrantFiled: March 19, 2021Date of Patent: December 7, 2021Assignee: Rewrite Therapeutics, Inc.Inventor: Schaked Omer Halperin
-
Patent number: 11173216Abstract: Described herein are CRISPR/Cas9 constructs designed for the C-terminal truncation of human amyloid precursor protein (APP) as well as methods of making and using such a construct. A Cas9 nuclease/gRNA ribonucleoprotein directs cleavage of an APP gene to provide a C-terminal truncated APP having a length of 659, 670, 676, or 686 amino acids, relative to the human or mouse APP sequence.Type: GrantFiled: January 18, 2019Date of Patent: November 16, 2021Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Subhojit Roy, Jichao Sun